Health · STAT+: On Wall Street, there’s trouble stirring for biotech
Missouri Attorney General warns Eli Lilly over 340B drug discount data requirements
Why it matters
This action highlights an escalating trend of state attorneys general intervening in federal drug pricing disputes and holding pharmaceutical companies accountable.
The brief
Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter on October 26, directing Eli Lilly to halt its policy requiring hospitals to supply claims data before receiving discounted medications through the federal 340B Drug Pricing Program, STAT reported.[1][2] Hanaway asserted that the pharmaceutical manufacturer breached its commitments by withholding discounts from institutions like University of Missouri Health Care even after data was provided, thereby violating state laws against misleading statements.[3] The warning underscores growing state-level pushback against drugmaker restrictions within public health pricing initiatives. STAT reported that the attorney general gave the company until November 26 to terminate the disputed policy.[4] It remains unconfirmed whether Eli Lilly will comply with the demand or pursue legal challenges against the state directive, according to the reporting.
What we don’t know yet
- Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly on October 26. Only statnews.com reports this so far.
- The cease-and-desist letter directed Eli Lilly to halt its policy requiring hospitals to supply claims data before receiving discounted medications through the 340B Drug Pricing Program. Only statnews.com reports this so far.
- Hanaway asserted that Eli Lilly withheld discounts from institutions like University of Missouri Health Care even after data was provided. Only statnews.com reports this so far.
- The attorney general gave the company until November 26 to terminate the disputed policy. Only statnews.com reports this so far.
Quick answers
- What happened?
- Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter on October 26, directing Eli Lilly to halt its policy requiring hospitals to supply claims data before receiving discounted medications through the federal 340B Drug Pricing Program, STAT reported. Hanaway asserted that the pharmaceutical manufacturer breached its commitments by withholding discounts from institutions like University of Missouri Health Care even after data was provided, thereby violating state laws against misleading statements. The warning underscores growing state-level pushback against drugmaker restrictions within public health pricing initiatives. STAT reported that the attorney general gave the company until November 26 to terminate the disputed policy. It remains unconfirmed whether Eli Lilly will comply with the demand or pursue legal challenges against the state directive, according to the reporting.
- Why does it matter?
- This action highlights an escalating trend of state attorneys general intervening in federal drug pricing disputes and holding pharmaceutical companies accountable.
- How was "Missouri Attorney General warns Eli Lilly over 340B drug discount data requirements" verified?
- Citelink grounded this brief in 1 source, including STAT News. Every claim links to its citation in the sources list below.
Grounding — every claim checked against sources
of 4 grounded3Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly on October 26.
The cease-and-desist letter directed Eli Lilly to halt its policy requiring hospitals to supply claims data before receiving discounted medications through the 340B Drug Pricing Program.
Hanaway asserted that Eli Lilly withheld discounts from institutions like University of Missouri Health Care even after data was provided.
The attorney general gave the company until November 26 to terminate the disputed policy.
Don't take our word for it
Run any claim in this Brief through Citelink's verification engine yourself.
Sources
How this brief was made
Citelink’s automated pipeline wrote this summary from the source listed above, then checked each claim against them before publishing. Briefs are not individually reviewed by a person before they go live, so read the original reporting for the full story.
Spotted an error? Request a correction · Corrections policy